In pilot clinical studies using patient serum samples assayed by surface plasmon resonance (SPR), SubB2M detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers.
“SubB2M is potentially one of the most exciting breakthroughs in cancer diagnostics that I have seen in 40 years of medical research."
Not much $ but the news will put it back on the buy side and watch this space lists.
- Forums
- ASX - By Stock
- Ann: BARD1 Awarded BTB Funding to Develop Breast Cancer Test
In pilot clinical studies using patient serum samples assayed by...
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
|
|||||
Last
62.5¢ |
Change
0.070(12.6%) |
Mkt cap ! $66.16M |
Open | High | Low | Value | Volume |
62.0¢ | 62.5¢ | 58.0¢ | $171.1K | 280.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2953 | 62.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
64.0¢ | 25000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1366 | 0.625 |
1 | 4409 | 0.620 |
1 | 3017 | 0.610 |
1 | 16930 | 0.605 |
1 | 10000 | 0.600 |
Price($) | Vol. | No. |
---|---|---|
0.640 | 25000 | 2 |
0.650 | 20000 | 1 |
0.655 | 2168 | 2 |
0.660 | 30000 | 1 |
0.665 | 8500 | 1 |
Last trade - 13.14pm 20/08/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |